BMI: A Flawed Measure of Health
It’s time we move beyond BMI and adopt a holistic approach to truly gauge health.
Novo Nordisk Aims to Succeed Where Sanofi Faltered Drugging a Weight-Loss Target
Novo Nordisk isn’t putting all of its weight loss drug hopes in the same basket. Its acquisition of Inversago Pharma for up to $1 billion will bring a biotech whose lead drug candidate has early clinical trial data showing significant weight loss.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Report: Fewer Adults Are Interested in Weight Loss Drugs If Not Covered by Insurance
About half of adults, or 45%, said they are at least somewhat interested in taking a “safe, effective weight-loss drug,” according to a new survey by KFF. However, just 16% of adults are still interested in taking weight-loss drugs if they’re not covered by insurance.
Eli Lilly’s Triple Mechanism Sets New High Mark for Weight Loss Drugs
Eli Lilly’s retatrutide led to an average weight reduction of 24.2%, or 58 pounds, after 48 weeks of treatment in Phase 2 testing. Based on these results, Lilly now plans a comprehensive Phase 3 program that will evaluate the once-weekly injectable drug in weight reduction as well as various complications of obesity.
Omada Launches Program To Support Patients on GLP-1s
Omada's new program provides coaching, peer support and educational materials to patients struggling with chronic obesity and taking GLP-1s. The company chose not to prescribe the weight loss drugs itself.
Amgen Weighs In to Chase Rival Obesity Drugs From Novo Nordisk and Eli Lilly
An Amgen drug led to weight loss that was sustained, clinical data that support advancing the molecule to a Phase 2 test expected to start in early 2023. While AMG 133 trails rival products from Novo Nordisk and Eli Lilly, Amgen hopes to offer patients a dosing edge.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.